SCHEMBL31366233

SCHEMBL31366233

CCCCCCCCCCc1ccc2c(c1)Nc1ccccc1S2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 11/20 0.50
GAA P10253 5/20 0.50
MAPT P10636 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALOX15 P16050 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
BCHE P06276 2/20 0.50
ACHE P22303 2/20 0.50
SNCA P37840 2/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP3A4 P08684 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
ALOX12 P18054 1/20 0.50
MAOA P21397 1/20 0.50
CNR1 P21554 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
HTR2C P28335 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7528258 1.00 NOX1 (0.50) NOX1GAAMAPTMEN1KMT2A
SCHEMBL17999681 1.00 NOX1 (0.50) NOX1GAAMAPTMEN1KMT2A
SCHEMBL7773452 1.00 NOX1 (0.50) NOX1GAAMAPTMEN1KMT2A
SCHEMBL17999668 0.98 NOX1 (0.52) NOX1GAAMAPTMEN1KMT2A
SCHEMBL7068258 0.94 NOX1 (0.53) NOX1GAAMAPTMEN1KMT2A
SCHEMBL29640446 0.92 PTGS2 (0.46) ACHECYP3A4ADORA3PTGS1SLC6A2
SCHEMBL7771194 0.92 PTGS2 (0.46) ACHECYP3A4ADORA3PTGS1SLC6A2
SCHEMBL227468 0.92 PTGS2 (0.46) ACHECYP3A4ADORA3PTGS1SLC6A2
SCHEMBL29640460 0.92 PTGS2 (0.46) ACHECYP3A4ADORA3PTGS1SLC6A2
SCHEMBL223661 0.91 NOX1 (0.50) NOX1GAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459910-B2 Mitochondrial therapeutic agents ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2025-11-04 US disclosed
US-20240409521-A1 MITOCHONDRIAL THERAPEUTIC AGENTS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2024-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409521-A1 MITOCHONDRIAL THERAPEUTIC AGENTS TFAM, TXNRD2, AIFM1 NOX1 489/4885GAA 998/4885MAPT 2301/4885
US-12459910-B2 Mitochondrial therapeutic agents TFAM, TXNRD2, AIFM1 NOX1 489/4885GAA 998/4885MAPT 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.